insights_auto
Why is INO down 2,41%?
Dive Deeperchevron_right
INO:NASDAQ
Inovio Pharmaceuticals Inc
1,62 $
arrow_downward
-2,41%(-0,040) 1D
1,61 $
arrow_downward
-0,71% (-0,012)bedtimeAfter hours
Closed: 4 қар., 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for INO...
Open
1,67 $
High
1,85 $
Low
1,55 $
Mkt. cap
167,50 млн
Avg. vol.
15,11 млн
Volume
21,38 млн
52-wk high
2,72 $
52-wk low
0,57 $
EPS
-1,17 $
Beta
1,71
Shares outstanding
103,40 млн
No. of employees
112
Open
1,67 $
High
1,85 $
Low
1,55 $
Mkt. cap
167,50 млн
Avg. vol.
15,11 млн
Volume
21,38 млн
52-wk high
2,72 $
52-wk low
0,57 $
EPS
-1,17 $
Beta
1,71
Shares outstanding
103,40 млн
No. of employees
112
News stories
From web sources and news partners
Kalkine
·
13 сағат бұрын
What Comes Next for Inovio (NASDAQ:INO) After a 224% Jump on Accelerated Approval?
News Corp
·
1 күн бұрын
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Yahoo Finance
·
2 күн бұрын
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
The Business Journals
·
2 күн бұрын
Inovio sets price for its first FDA-approved drug at $115,000 per dose
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc